Idiopathic pulmonary fibrosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Idiopathic pulmonary fibrosis }} | {{Idiopathic pulmonary fibrosis }} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AEL}} | ||
==Overview== | ==Overview== | ||
==Medical Therapy== | ==Medical Therapy== | ||
| Line 13: | Line 13: | ||
=== Medical treatment === | === Medical treatment === | ||
* There is no specific treatment for idiopathic pulmonary fibrosis. However, there are two medications, nintedanib and pirfenidone, that can be administrated in order to slow the disease progression.<ref name="pmid261771832">{{cite journal| author=Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J et al.| title=An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. | journal=Am J Respir Crit Care Med | year= 2015 | volume= 192 | issue= 2 | pages= e3-19 | pmid=26177183 | doi=10.1164/rccm.201506-1063ST | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26177183 }}</ref> | * There is no specific treatment for idiopathic pulmonary fibrosis. However, there are two medications, nintedanib and pirfenidone, that can be administrated in order to slow the disease progression.<ref name="pmid261771832">{{cite journal| author=Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J et al.| title=An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. | journal=Am J Respir Crit Care Med | year= 2015 | volume= 192 | issue= 2 | pages= e3-19 | pmid=26177183 | doi=10.1164/rccm.201506-1063ST | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26177183 }}</ref> | ||
==References== | ==References== | ||
Revision as of 13:59, 3 April 2018
|
Idiopathic pulmonary fibrosis Microchapters |
|
Differentiating Idiopathic pulmonary fibrosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Idiopathic pulmonary fibrosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Idiopathic pulmonary fibrosis medical therapy |
|
Directions to Hospitals Treating Idiopathic pulmonary fibrosis |
|
Risk calculators and risk factors for Idiopathic pulmonary fibrosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
Medical Therapy
Supportive care
- Patients with idiopathic pulmonary fibrosis receive supportive care alongside the medical therapy.[1]
- Supportive care measures include the following:
- Mechanical ventilation: Nearly all the patients with IPF require oxygen supplementation.
- Pulmonary rehabilitation
- Vaccination against possible causes of pulmonary inflammation as influenza and pneumococcal polysacchride capsule vaccines.[2]
Medical treatment
- There is no specific treatment for idiopathic pulmonary fibrosis. However, there are two medications, nintedanib and pirfenidone, that can be administrated in order to slow the disease progression.[3]
References
- ↑ Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK; et al. (2011). "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management". Am J Respir Crit Care Med. 183 (6): 788–824. doi:10.1164/rccm.2009-040GL. PMC 5450933. PMID 21471066. Review in: Ann Intern Med. 2011 Jun 21;154(12):JC6-8
- ↑ Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG; et al. (2014). "Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Morb Mortal Wkly Rep. 63 (37): 822–5. PMC 5779453. PMID 25233284.
- ↑ Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J; et al. (2015). "An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline". Am J Respir Crit Care Med. 192 (2): e3–19. doi:10.1164/rccm.201506-1063ST. PMID 26177183.